Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Clovis Oncology Inc CLVSQ

Healthcare Biotechnology
Clovis Oncology, Inc. is a biopharmaceutical company. The Company is focused on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe and additional international markets. Its segments include U.S. and ex-U.S. Its product, Rubraca, is an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP) marketed in the United States for two indications... see more

Recent & Breaking News (PINL:CLVSQ)

Clovis Oncology to Announce Fourth Quarter 2021 and Year End 2021 Financial Results and Host Webcast Conference Call

Business Wire February 10, 2022

Clovis Oncology Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2021

Business Wire January 10, 2022

Clovis Oncology Highlights FAP-2286 Preclinical Data Presented at the Targeted Radiopharmaceuticals Summit

Business Wire December 9, 2021

Clovis Oncology Announces Third Quarter 2021 Operating Results

Business Wire November 3, 2021

Clovis Oncology to Announce Third Quarter 2021 Financial Results and Host Webcast Conference Call on November 3

Business Wire October 20, 2021

Clovis Oncology and ITM Announce Lutetium-177 Clinical Supply Agreement

Business Wire October 19, 2021

Pan-Cancer Analysis Suggests Fibroblast Activation Protein (FAP) is an Attractive Target for Peptide-Targeted Radionuclide Therapy with FAP-2286

Business Wire October 7, 2021

Clovis Oncology Retires Remaining 2021 Notes and Raises Additional Capital through its ATM Equity Offering Program

Business Wire September 20, 2021

Clovis Oncology Announces Renewal of At-The-Market Equity Offering Program

Business Wire August 16, 2021

Clovis Oncology Announces Second Quarter 2021 Operating Results

Business Wire August 4, 2021

Clovis Oncology to Announce Second Quarter 2021 Financial Results and Host Webcast Conference Call on August 4

Business Wire July 21, 2021

Clovis Oncology Appoints Dr. Ronit Simantov to its Board of Directors

Business Wire July 12, 2021

Initial Clinical Experience of FAP-2286 in Independent Named Patient Use Published in The Journal of Nuclear Medicine

Business Wire June 28, 2021

Clovis Oncology Announces LuMIERE Clinical Trial Evaluating Novel Peptide-Targeted Radionuclide Therapy FAP-2286 Now Open for Enrollment

Business Wire June 23, 2021

Clovis Oncology Announces Partial Adjournment of Annual Meeting of Stockholders

Business Wire June 10, 2021

Clovis Oncology Highlights Rubraca® (rucaparib) and Lucitanib Data at 2021 ASCO Annual Meeting

Business Wire May 19, 2021

Clovis Oncology Announces At-The-Market Equity Offering Program

Business Wire May 17, 2021

Clovis Oncology Announces First Quarter 2021 Operating Results

Business Wire May 5, 2021

Clovis Oncology to Present at the Bank of America 2021 Health Care Conference

Business Wire April 28, 2021

Clovis Oncology to Announce First Quarter 2021 Financial Results and Host Webcast Conference Call on May 5

Business Wire April 21, 2021